Cooley, Davis Polk Rep Lung Disease Biopharma's $69M IPO
AN2 Therapeutics Inc., a biopharmaceutical startup focused on developing treatments for a rare form of lung disease, began trading on the Nasdaq on Friday after raising $69 million in an initial...To view the full article, register now.
Already a subscriber? Click here to view full article